Church of PeptidesSearch
Portrait of Selank
Pilgrims · 1990s–2000s

Selank

The Quiet Envoy

Moscow, Russia

Selank is an experimental peptide studied for anxiety-related effects. Its clinical record includes a small Russian comparison with the anxiolytic medazepam. A measured change in anxiety symptoms within such a study is different from establishing broad effectiveness or dependable long-term safety.

Evidence ladder: Controlled human evidenceEducational record
ClassificationPilgrims
Evidence summaryControlled human evidence
OriginMoscow, Russia
Scientific record

What the evidence says

Established role or proposed benefit

  • Studied for anxiety-related and neurobehavioral effects.
  • Derived from a tuftsin-related peptide concept.

Side effects, risks, and limits

  • Not FDA-approved.
  • Evidence outside its regional research tradition remains limited.
Doctide’s verdict

The Quiet Envoy has a small human study behind the story, not a settled treatment standard. Doctide treats the reported anxiety findings as a reason for further investigation, with product and long-term safety questions still open.

Documented history

Where the real story begins

A 2008 Russian-language study enrolled sixty-two patients with generalized anxiety disorder or neurasthenia: thirty received Selank and thirty-two received medazepam. The investigators reported similar anxiety effects. This provides a concrete clinical milestone without inventing an exact discovery date from the later literature. Historical source.

Moscow, Russia · 1990s–2000s
Book of the Canon · comic scripture

The laboratory legend

Selank entered without announcing herself. Ten minutes later the arguments were softer, but Doctide still demanded controlled trials before canonization.

This bold passage is invented comedy, not scientific or historical fact.
Editorial recordProfile editorial revision: October 4, 2026Prepared under the Church of Peptides evidence standardEditorial review: Church of PeptidesIndependent clinical review: none to dateContent evidence reviewed: September 12, 2026
Evidence ledger

Sources

Source links checked: October 4, 2026. A small comparative human study has limited generalizability and does not establish broad wellness claims.

  1. Small comparative study in anxiety disorders, 2008
  2. FDA compounding safety concerns

Fiction disclosure: The bold laboratory legend is invented. The historical and scientific sections are factual summaries; no invented connective events were added.

Educational entertainment only. Not medical advice, diagnosis, dosing guidance, or a recommendation to obtain or use a product.